Company news

Abivax SA news in 2026

Abivax SA's news releases, calls and decks from 2026, newest first.

View company

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 30.09.26

October 22, 2026

Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026

September 30, 2026

Abivax présentera des données sur l’obéfazimod lors de l’United European Gastroenterology (UEG) Week 2026

September 29, 2026

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.08.26

September 24, 2026

Abivax Presents Business Updates and First Half 2026 Financial Results

September 21, 2026

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod

July 30, 2026

Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments

July 23, 2026

Abivax Announces Closing of $920 Million Public Offering

July 6, 2026

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)

July 2, 2026

Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

July 1, 2026

Abivax Announces Launch of Public Offering of American Depositary Shares

June 30, 2026

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory UC Patients and Strengthening the Phase 3 Maintenance Safety Database

June 29, 2026

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database

June 29, 2026

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

June 1, 2026

Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC

May 22, 2026

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

May 22, 2026

Abivax Announces Results of its May 11, 2026 Annual General Meeting

May 11, 2026

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (EUR38.5M) Offering of American Depositary Shares

May 7, 2026

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

May 5, 2026

Abivax to Present Data on Obefazimod at Digestive Disease Week®

April 22, 2026

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

April 20, 2026

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

April 1, 2026

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates

March 23, 2026

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

February 21, 2026

Abivax Provides 2026 Corporate Outlook

January 7, 2026

Decks in 2026